Peter A Castillo, MD
Obstetrics/Gynecology · Los Gatos
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
Offices
1 location · Peter A Castillo MD Inc · 2 clinicians in this group
Looking this up.
Hospitals listed: Contra Costa Regional Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Castillo’s office at (925) 905-9922 to ask if they take your plan before you enroll.
California Medical Board record
Licence A109681 · Current
Licensed to practise in California · since 2009 · expires 2026-12-31 · Autonomous University of Guadalajara Faculty of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
State licence records
1 licence
- Florida ME96973Medical Doctor · since 2006 · expires 2011-01-31Null And VoidNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
School, training and certification
2 placements
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Education
- University Autonoma de Guadalajara · MD1997–2000Medical school
Residency and fellowship
- St Barnabas Medical Center, Obstetrics and GynecologyLIVINGSTON, NJ · 2003–2006
- St Barnabas Medical Center, Obstetrics and GynecologyLIVINGSTON, NJ · 2002–2003
What else the board holds
Hospitals they may admit to
Where the clinician told their state board they may admit and treat patients.
- Cleveland Clinic Florida
Also licensed in
States the clinician told their board they are also licensed in. Only the states we check are verified.
New Jersey
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Contra Costa Regional Medical CenterMartinez, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Contra Costa Health ServicesPatients rate it 3 of 5 · 73% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.167, Oct 2024 – Sep 2025
See every measure and the patient survey for Contra Costa Regional Medical Center
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 1 better, 4 the same, 0 worse of 5 measures. Readmissions: 1 better, 4 the same, 1 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.167 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.99 (0 to 2.04) · 188 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.08 (0.63 to 1.53) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.2 · 44 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.8 · 111 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.4 · 114 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.3 · 27 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 321 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.44) · 1,181 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.05 to 0.47) · 1,198 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.2 (0.67 to 5.72) · 216 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.64 (0 to 3.36) · 71 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.5 (0.82 to 4.18) · 195 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.36 (1.01 to 19.71) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.88 (0.69 to 9.08) · 57 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.07 (0.55 to 3.58) · 67 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.93 (0 to 2.03) · 981 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.948 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 2.027 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.3 · 101 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 52.2 · 126 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -53.6 · 112 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 87 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.7 to 8.6) · 95 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (8.8 to 17.8) · 95 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.2 · 35 cases | None | Jul 2023 – Jun 2025 |
What patients said (521 patients answered, 10% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 79% |
| Nurses "always" communicated well | 76% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 66% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 78% |
| Nurses "always" explained things so they could understand | 72% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 45% |
| "YES", patients would definitely recommend the hospital | 73% |
| Staff "always" explained possible side effects | 54% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
Original Medicare doctor bills
$58,252
Medicare paid this office $58,252 for 115 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 23 | $9,122 | $397 |
| Return visit (30+ min) | 58 | $8,728 | $115 |
| Short return visit (20+ min) | 62 | $7,595 | $82 |
| New patient visit (45+ min) | 58 | $7,423 | $128 |
| Insertion of device into abdomen with pressure and urine flow rate study | 23 | $4,580 | $199 |
See all 8 services
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 23 | $9,122 | $397 |
| Return visit (30+ min) | 58 | $8,728 | $115 |
| Short return visit (20+ min) | 62 | $7,595 | $82 |
| New patient visit (45+ min) | 58 | $7,423 | $128 |
| Insertion of device into abdomen with pressure and urine flow rate study | 23 | $4,580 | $199 |
| Insertion of temporary bladder tube | 74 | $3,910 | $41 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 24 | $724 | $30 |
| Pelvic exam | 22 | $660 | $25 |
Procedures Medicare counted
| Removal of the uterus | 1-10 | None |
Who their Medicare patients are
115 Original Medicare patients in 2024. Average age 73 · Women 100% · Also on Medicaid 39% · Health risk score 0.92. Above the middle of the specialty; the typical obstetrics & gynecology clinician is at 0.88.
Conditions among them: High blood pressure 69% · Diabetes 33% · Depression 22% · Coronary heart disease 11% · Chronic kidney disease 10% · Cancer 10% · Atrial fibrillation 10% · Stroke 10%.
The office billed $261,328, Medicare allowed $77,113 and paid $58,252; for 1,125 services of 28 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 115 | 1,125 | 73 | 0.92 | $261,328 | $58,252 |
| 2023 | 96 | 1,340 | 75 | 0.93 | $154,245 | $41,120 |
| 2022 | 100 | 992 | 74 | 0.71 | $186,973 | $46,967 |
| 2021 | 86 | 1,042 | 73 | 0.72 | $155,850 | $40,448 |
| 2020 | 88 | 851 | 74 | 0.82 | $200,016 | $42,593 |
| 2019 | 108 | 843 | 73 | 0.92 | $332,706 | $67,389 |
| 2018 | 103 | 1,263 | 72 | 0.78 | $372,428 | $73,849 |
| 2017 | 85 | 692 | 72 | 0.94 | $356,722 | $66,506 |
| 2016 | 53 | 460 | 73 | 0.94 | $239,266 | $43,149 |
| 2015 | 22 | 181 | 76 | 1.37 | $157,225 | $20,934 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 7 services
| Short return visit (20+ min) | 59 | $7,704 | $81 |
| New patient visit (45+ min) | 35 | $5,183 | $148 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 11 | $4,414 | $401 |
| Return visit (30+ min) | 21 | $3,153 | $121 |
| Insertion of temporary bladder tube | 41 | $2,415 | $43 |
| Insertion of device into abdomen with pressure and urine flow rate study | 11 | $2,260 | $205 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 11 | $345 | $31 |
2022: 7 services
| Short return visit (20+ min) | 64 | $9,276 | $81 |
| New patient visit (45+ min) | 36 | $5,388 | $150 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 13 | $5,382 | $414 |
| Return visit (30+ min) | 32 | $4,106 | $103 |
| Insertion of device into abdomen with pressure and urine flow rate study | 13 | $2,720 | $209 |
| Insertion of temporary bladder tube | 38 | $1,823 | $42 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 13 | $349 | $27 |
2021: 7 services
| Short return visit (20+ min) | 60 | $8,710 | $86 |
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 12 | $4,954 | $413 |
| Return visit (30+ min) | 25 | $3,190 | $106 |
| New patient visit (45+ min) | 19 | $2,792 | $147 |
| Insertion of device into abdomen with pressure and urine flow rate study | 12 | $2,402 | $200 |
| Insertion of temporary bladder tube | 29 | $1,744 | $45 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 12 | $360 | $30 |
2020: 7 services
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 23 | $8,837 | $384 |
| Return visit (30+ min) | 52 | $6,349 | $91 |
| New patient visit (60+ min) | 25 | $4,461 | $178 |
| Insertion of device into abdomen with pressure and urine flow rate study | 23 | $3,846 | $167 |
| Short return visit (20+ min) | 35 | $3,512 | $62 |
| Insertion of temporary bladder tube | 28 | $1,489 | $41 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 23 | $668 | $29 |
2019: 8 services
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 42 | $15,173 | $361 |
| Return visit (30+ min) | 57 | $8,838 | $102 |
| Creation of sling around urethra in female to control leakage | 11 | $6,580 | $598 |
| Short return visit (20+ min) | 50 | $6,026 | $64 |
| New patient visit (60+ min) | 33 | $5,889 | $178 |
| Insertion of device into abdomen with pressure and urine flow rate study | 41 | $5,803 | $142 |
| Insertion of temporary bladder tube | 42 | $2,684 | $43 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 43 | $1,410 | $33 |
2018: 11 services
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 46 | $15,236 | $331 |
| Return visit (30+ min) | 55 | $7,353 | $97 |
| Short return visit (20+ min) | 56 | $6,483 | $67 |
| New patient visit (60+ min) | 33 | $6,119 | $185 |
| Creation of sling around urethra in female to control leakage | 11 | $5,795 | $527 |
| Insertion of device into abdomen with pressure and urine flow rate study | 45 | $5,014 | $111 |
| Insertion of temporary bladder tube | 50 | $3,170 | $45 |
| New patient visit (45+ min) | 14 | $2,041 | $146 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 45 | $1,475 | $33 |
| Fitting and insertion of vaginal support device | 12 | $986 | $62 |
| Pessary, reusable, non rubber, any type | 11 | $588 | $39 |
2017: 8 services
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 41 | $13,608 | $324 |
| Return visit (30+ min) | 54 | $7,329 | $95 |
| Short return visit (20+ min) | 35 | $4,775 | $63 |
| Insertion of device into abdomen with pressure and urine flow rate study | 41 | $4,513 | $107 |
| New patient visit (60+ min) | 25 | $4,365 | $175 |
| Insertion of temporary bladder tube | 42 | $2,129 | $43 |
| New patient visit (45+ min) | 14 | $2,040 | $146 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 42 | $1,412 | $33 |
2016: 8 services
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 25 | $8,422 | $337 |
| New patient visit (60+ min) | 30 | $5,515 | $184 |
| Short return visit (20+ min) | 21 | $2,815 | $67 |
| Insertion of device into abdomen with pressure and urine flow rate study | 25 | $2,778 | $111 |
| Return visit (30+ min) | 15 | $2,750 | $95 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 25 | $2,368 | $95 |
| Insertion of temporary bladder tube | 23 | $1,333 | $51 |
| Urinalysis, manual test | 22 | $133 | $3 |
2015: 6 services
| Complex measurement of pressure of urine flow in bladder with urethra pressure and voiding pressure studies | 14 | $4,751 | $339 |
| New patient visit (60+ min) | 16 | $3,027 | $189 |
| Return visit (30+ min) | 14 | $2,024 | $101 |
| Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | 12 | $1,146 | $96 |
| Insertion of temporary bladder tube | 11 | $746 | $53 |
| Urinalysis, manual test | 16 | $126 | $3 |
Medicaid work
$5,087 in 2024
Medicaid paid $5,087 for 139 billed services this clinician did in 2024, up to 21 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Insertion of non-indwelling bladder catheter (eg, straight catheterization for residual urine) | 44 | $2,419 |
| New patient visit (45+ min) | 12 | $2,379 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, without microscopy | 83 | $289 |
| 2024 | 139 | 3 | 21 | $5,087 |
| 2023 | 73 | 2 | 17 | $842 |
| 2022 | 529 | 3 | 29 | $69,989 |
| 2021 | 525 | 3 | 25 | $74,929 |
| 2020 | 410 | 3 | 21 | $59,873 |
| 2019 | 257 | 3 | 23 | $37,492 |
| 2018 | 242 | 4 | 20 | $41,416 |
See the largest Medicaid services in earlier years
2023
| Insertion of non-indwelling bladder catheter (eg, straight catheterization for residual urine) | 12 | $630 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, without microscopy | 61 | $212 |
2022
| Clinic visit/encounter, all-inclusive | 147 | $49,315 |
| Service | 252 | $20,674 |
| Service | 130 | $0 |
2021
| Clinic visit/encounter, all-inclusive | 182 | $60,162 |
| Service | 180 | $14,767 |
| Service | 163 | $0 |
2020
| Clinic visit/encounter, all-inclusive | 148 | $48,469 |
| Service | 139 | $11,404 |
| Service | 123 | $0 |
2019
| Clinic visit/encounter, all-inclusive | 74 | $23,627 |
| Service | 169 | $13,865 |
| Service | 14 | $0 |
2018
| Clinic visit/encounter, all-inclusive | 100 | $31,436 |
| Service | 103 | $8,450 |
| Return visit (30+ min) | 12 | $1,436 |
| Urinalysis, by dip stick or tablet reagent for bilirubin, glucose, hemoglobin, ketones, leukocytes, nitrite, pH, protein, specific gravity, urobilinogen, any number of these constituents; non-automated, without microscopy | 27 | $94 |
Drugs they prescribed that Part D paid
$138,761
Pharmacies billed $138,761 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
438 generic and 161 brand-name prescriptions · $138,761 in drug cost · 53 antibiotic prescriptions to 29 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Myrbetriq | 69 | $72,538 | $1,051 |
| Gemtesa | 28 | $21,294 | $761 |
| Imvexxy | 38 | $15,814 | $416 |
| Estradiol | 161 | $9,781 | $61 |
| Trospium Chloride Er | 16 | $5,364 | $335 |
See all 14 drugs
| Myrbetriq | 69 | $72,538 | $1,051 |
| Gemtesa | 28 | $21,294 | $761 |
| Imvexxy | 38 | $15,814 | $416 |
| Estradiol | 161 | $9,781 | $61 |
| Trospium Chloride Er | 16 | $5,364 | $335 |
| Liothyronine | 31 | $2,228 | $72 |
| Progesterone | 44 | $2,013 | $46 |
| NP Thyroid | 25 | $1,474 | $59 |
| Oxybutynin Chloride Er | 19 | $716 | $38 |
| Nitrofurantoin Mono-Macro | 24 | $304 | $13 |
| Spironolactone | 27 | $256 | $9 |
| Clotrimazole-Betamethasone | 12 | $242 | $20 |
| Levothyroxine | 27 | $218 | $8 |
| Cephalexin | 11 | $116 | $11 |
Year by year
| 2024 | 638 | 160 | None | 25% | $138,761 |
| 2023 | 679 | 141 | None | 23% | $148,860 |
| 2022 | 621 | 144 | None | 15% | $90,056 |
| 2021 | 540 | 127 | None | 22% | $91,923 |
| 2020 | 507 | 117 | None | 22% | $76,219 |
| 2019 | 629 | 129 | 2% (15) | None | $77,884 |
| 2018 | 463 | 99 | None | 20% | $60,828 |
| 2017 | 265 | 86 | 5% (12) | None | $45,599 |
| 2016 | 214 | 81 | None | 20% | $37,354 |
| 2015 | 307 | 138 | None | 15% | $55,870 |
| 2014 | 729 | 261 | 3% (20) | 15% | $135,436 |
| 2013 | 792 | 290 | 4% (33) | 15% | $151,416 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 16 drugs
| Myrbetriq | 80 | $79,669 | $996 |
| Estradiol | 157 | $18,177 | $116 |
| Ozempic | 13 | $14,727 | $1,133 |
| Imvexxy | 35 | $14,350 | $410 |
| Progesterone | 41 | $3,034 | $74 |
| Liothyronine | 38 | $2,653 | $70 |
| NP Thyroid | 43 | $2,063 | $48 |
| Oxybutynin Chloride Er | 27 | $1,924 | $71 |
| Trospium Chloride Er | 14 | $1,819 | $130 |
| Armour Thyroid | 18 | $1,238 | $69 |
| Levothyroxine | 34 | $536 | $16 |
| Nitrofurantoin Mono-Macro | 19 | $281 | $15 |
| Spironolactone | 31 | $241 | $8 |
| Nitrofurantoin | 15 | $178 | $12 |
| Cephalexin | 18 | $151 | $8 |
| Metformin | 12 | $101 | $8 |
2022: 13 drugs
| Myrbetriq | 45 | $39,851 | $886 |
| Estradiol | 164 | $20,408 | $124 |
| Imvexxy | 21 | $7,545 | $359 |
| Oxybutynin Chloride Er | 50 | $3,559 | $71 |
| Liothyronine | 40 | $2,943 | $74 |
| Progesterone | 50 | $2,354 | $47 |
| NP Thyroid | 50 | $1,652 | $33 |
| Levothyroxine | 25 | $503 | $20 |
| Nitrofurantoin Mono-Macro | 15 | $268 | $18 |
| Spironolactone | 19 | $267 | $14 |
| Metformin | 29 | $233 | $8 |
| Clotrimazole-Betamethasone | 12 | $215 | $18 |
| Cephalexin | 18 | $201 | $11 |
2021: 14 drugs
| Myrbetriq | 43 | $39,240 | $913 |
| Estradiol | 107 | $15,750 | $147 |
| Imvexxy | 35 | $8,596 | $246 |
| Premarin | 20 | $8,519 | $426 |
| Oxybutynin Chloride Er | 67 | $5,056 | $75 |
| Liothyronine | 37 | $2,975 | $80 |
| Progesterone | 38 | $2,109 | $56 |
| Armour Thyroid | 20 | $1,368 | $68 |
| Levothyroxine | 30 | $682 | $23 |
| NP Thyroid | 18 | $595 | $33 |
| Clotrimazole-Betamethasone | 13 | $234 | $18 |
| Nitrofurantoin Mono-Macro | 14 | $212 | $15 |
| Spironolactone | 13 | $137 | $11 |
| Cephalexin | 11 | $104 | $9 |
2020: 15 drugs
| Myrbetriq | 48 | $28,096 | $585 |
| Estradiol | 76 | $13,516 | $178 |
| Estrace | 25 | $8,833 | $353 |
| Premarin | 22 | $8,479 | $385 |
| Trospium Chloride Er | 15 | $4,216 | $281 |
| Oxybutynin Chloride Er | 61 | $3,832 | $63 |
| Liothyronine | 56 | $2,051 | $37 |
| Levothyroxine | 42 | $733 | $17 |
| Progesterone | 11 | $553 | $50 |
| Clobetasol Propionate | 11 | $500 | $45 |
| Armour Thyroid | 11 | $310 | $28 |
| Clotrimazole-Betamethasone | 12 | $194 | $16 |
| Nitrofurantoin Mono-Macro | 15 | $194 | $13 |
| Ibuprofen | 14 | $102 | $7 |
| Metformin | 16 | $98 | $6 |
2019: 15 drugs
| Myrbetriq | 54 | $29,584 | $548 |
| Estradiol | 70 | $15,518 | $222 |
| Premarin | 19 | $7,310 | $385 |
| Estrace | 21 | $7,304 | $348 |
| Vesicare | 11 | $4,194 | $381 |
| Oxybutynin Chloride Er | 83 | $3,977 | $48 |
| Liothyronine | 59 | $1,607 | $27 |
| Levothyroxine | 60 | $859 | $14 |
| Nitrofurantoin Mono-Macro | 17 | $637 | $37 |
| Clotrimazole-Betamethasone | 17 | $358 | $21 |
| Cephalexin | 44 | $189 | $4 |
| Ciprofloxacin | 22 | $182 | $8 |
| Metformin | 41 | $151 | $4 |
| Sulfamethoxazole-Trimethoprim | 13 | $69 | $5 |
| Hydrocodone-Acetaminophen | 12 | $52 | $4 |
2018: 16 drugs
| Myrbetriq | 27 | $13,821 | $512 |
| Estradiol | 50 | $10,948 | $219 |
| Estrace | 27 | $9,678 | $358 |
| Premarin | 22 | $7,914 | $360 |
| Vesicare | 20 | $7,182 | $359 |
| Oxybutynin Chloride Er | 51 | $3,360 | $66 |
| Progesterone | 14 | $2,008 | $143 |
| Liothyronine | 37 | $1,199 | $32 |
| Levothyroxine | 29 | $446 | $15 |
| Armour Thyroid | 11 | $421 | $38 |
| Hydrocortisone | 16 | $259 | $16 |
| Spironolactone | 13 | $166 | $13 |
| Cephalexin | 39 | $161 | $4 |
| Ibuprofen | 14 | $81 | $6 |
| Metformin | 16 | $74 | $5 |
| Ciprofloxacin | 12 | $68 | $6 |
2017: 5 drugs
| Estrace | 62 | $18,174 | $293 |
| Myrbetriq | 22 | $11,055 | $503 |
| Premarin | 27 | $9,086 | $337 |
| Oxybutynin Chloride Er | 38 | $2,983 | $79 |
| Cephalexin | 24 | $101 | $4 |
2016: 4 drugs
| Estrace | 70 | $21,050 | $301 |
| Premarin | 26 | $7,350 | $283 |
| Oxybutynin Chloride Er | 18 | $1,986 | $110 |
| Cephalexin | 28 | $117 | $4 |
2015: 6 drugs
| Estrace | 98 | $22,945 | $234 |
| Oxybutynin Chloride Er | 72 | $10,202 | $142 |
| Trospium Chloride Er | 24 | $9,752 | $406 |
| Premarin | 37 | $8,242 | $223 |
| Trospium Chloride | 15 | $2,181 | $145 |
| Cephalexin | 12 | $29 | $2 |
2014: 11 drugs
| Trospium Chloride Er | 98 | $45,466 | $464 |
| Estrace | 205 | $42,602 | $208 |
| Oxybutynin Chloride Er | 117 | $15,157 | $130 |
| Premarin | 82 | $13,703 | $167 |
| Trospium Chloride | 41 | $8,100 | $198 |
| Imipramine | 34 | $930 | $27 |
| Ibuprofen | 39 | $476 | $12 |
| Cephalexin | 20 | $304 | $15 |
| Ciprofloxacin | 15 | $207 | $14 |
| Hydrocodone-Acetaminophen | 18 | $160 | $9 |
| Sulfamethoxazole-Trimethoprim | 13 | $91 | $7 |
2013: 11 drugs
| Estrace | 228 | $43,019 | $189 |
| Trospium Chloride | 98 | $41,001 | $418 |
| Trospium Chloride Er | 52 | $28,340 | $545 |
| Oxybutynin Chloride Er | 104 | $15,503 | $149 |
| Premarin | 104 | $15,401 | $148 |
| Imipramine | 33 | $903 | $27 |
| Ibuprofen | 45 | $478 | $11 |
| Ciprofloxacin | 23 | $313 | $14 |
| Hydrocodone-Acetaminophen | 31 | $304 | $10 |
| Cephalexin | 19 | $264 | $14 |
| Sulfamethoxazole-Trimethoprim | 11 | $78 | $7 |
Money from drug and device companies
$385 in 2025
| 2025 | 10 | 16 | None | $385 |
| 2024 | 9 | 21 | None | $632 |
| 2023 | 7 | 25 | $455 | $3,339 |
| 2022 | 8 | 59 | $20,700 | $23,630 |
| 2021 | 7 | 25 | $400 | $2,213 |
| 2020 | 5 | 10 | $2,025 | $2,352 |
| 2019 | 8 | 64 | $57,020 | $62,740 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Botox | $71 | 3 payments
|
| Valencia Technologies | Ecoin Device Kit | $69 | 2 payments
|
| Lilly USA | Mounjaro | $45 | 2 payments
|
| Mayne Pharma Commercial | None | $43 | 3 payments
|
| Sumitomo Pharma America | Gemtesa | $37 | 1 payment
|
| Bluewind Medical | Revi | $31 | 1 payment
|
See all 16 published payments
| Abbvie | Meals · 2025-11-05 | Botox | $21 |
| Acella Pharmaceuticals | Meals · 2025-11-04 | NP Thyroid 60 | $25 |
| Abbvie | Meals · 2025-10-08 | Botox | $22 |
| Mayne Pharma Commercial | Meals · 2025-08-21 | None | $6 |
| Valencia Technologies | Meals · 2025-06-20 | Ecoin Device Kit | $35 |
| Valencia Technologies | Meals · 2025-06-20 | Ecoin Device Kit | $35 |
| Mayne Pharma Commercial | Meals · 2025-06-20 | None | $7 |
| Laborie Medical Technologies | Meals · 2025-06-12 | None | $22 |
| Abbvie | Meals · 2025-05-31 | Botox | $27 |
| Bluewind Medical | Meals · 2025-05-28 | Revi | $31 |
| Mayne Pharma Commercial | Meals · 2025-05-17 | None | $31 |
| Lilly USA | Meals · 2025-05-07 | Mounjaro | $26 |
| Lilly USA | Meals · 2025-05-06 | Zepbound | $19 |
| Astellas Pharma US | Meals · 2025-04-23 | Veozah | $23 |
| Boston Scientific | Meals · 2025-03-15 | Solyx Sis System | $20 |
| Sumitomo Pharma America | Meals · 2025-01-24 | Gemtesa | $37 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $632
| Caldera Medical | Desara | $168 | 3 payments
|
| Boston Scientific | Advantage System | $128 | 1 payment
|
| Sumitomo Pharma America | Gemtesa | $97 | 3 payments
|
| Mayne Pharma Commercial | None | $60 | 8 payments
|
| Coloplast | Saffron | $56 | 1 payment
|
| Abbvie | Botox | $49 | 2 payments
|
| Bluewind Medical | Revi | $34 | 1 payment
|
| Astellas Pharma US | Veozah | $24 | 1 payment
|
| Acella Pharmaceuticals | NP Thyroid 60 | $15 | 1 payment
|
2023: $3,339
| Boston Scientific | Upsylon | $1,856 | 8 payments
|
| Valencia Technologies | Ecoin Device Kit | $623 | 2 payments
|
| Medtronic | None | $455 | 2 payments
|
| Caldera Medical | Desara | $196 | 2 payments
|
| Astellas Pharma US | Veozah | $150 | 5 payments
|
| Mayne Pharma Commercial | None | $38 | 5 payments
|
| Axonics | Axonics | $22 | 1 payment
|
2022: $23,630
| Boston Scientific | Solyx Sis System | $23,128 | 26 payments
|
| TherapeuticsMD | Annovera | $202 | 24 payments
|
| Valencia Technologies | Ecoin Device Kit | $170 | 2 payments
|
| Astellas Pharma US | Myrbetriq | $50 | 3 payments
|
| CooperSurgical | Endosee | $26 | 1 payment
|
| Coloplast | Restorelle | $25 | 1 payment
|
| Allergan | None | $15 | 1 payment
|
| Caldera Medical | Desara | $14 | 1 payment
|
2021: $2,213
| Axonics | Bulkamid | $1,393 | 8 payments
|
| Boston Scientific | Solyx | $555 | 8 payments
|
| Coloplast | Altis | $89 | 1 payment
|
| Galderma Laboratories L.P. | None | $62 | 2 payments
|
| Allergan | Botox | $48 | 2 payments
|
| Astellas Pharma US | Myrbetriq | $45 | 3 payments
|
| Merz North America | Xeomin | $20 | 1 payment
|
2020: $2,352
| Boston Scientific | Ams | $2,240 | 5 payments
|
| Astellas Pharma US | Myrbetriq | $48 | 2 payments
|
| Allergan | Botox | $22 | 1 payment
|
| TherapeuticsMD | Annovera | $22 | 1 payment
|
| Olympus America | Contained Tissue Extraction Syst | $21 | 1 payment
|
2019: $62,740
| Boston Scientific | Solyx | $62,396 | 52 payments
|
| Coloplast | Axis | $98 | 1 payment
|
| TherapeuticsMD | Bijuva | $73 | 4 payments
|
| Teva Pharmaceuticals USA | Ajovy | $62 | 2 payments
|
| Medline Industries | None | $44 | 2 payments
|
| AMAG Pharmaceuticals | Vyleesi | $23 | 1 payment
|
| Allergan | Botox | $23 | 1 payment
|
| Astellas Pharma US | Vesicare | $22 | 1 payment
|
Professional record
- NPI
- 1164521035
- Licence
- CA A109681, FL ME96973California A109681: Current · expires 2026-12-31Florida ME96973: Null And Void
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207VF0040X (207VF0040X); Federal specialty code 207V00000X (207V00000X)
- Mailing address
- 15215 National Ave Ste 104, Los Gatos, CA, 95032
- NPI first listed
- 2006-09-21
- NPI last updated
- 2022-07-21
This is when the NPI record was last certified, not a medical board exam.